Central Pain Syndrome Management Market

Central Pain Syndrome Management Market Size, Market Forecast and Outlook By FMI

Summary of the Central Pain Syndrome Management Market

• Demand and Growth Drivers
  • Rising prevalence of stroke, multiple sclerosis, and spinal cord injury is expanding the patient population presenting with central pain syndrome.
  • Advancement of neuromodulation technologies is broadening treatment options beyond pharmacological management.
  • Non-opioid treatment preferences are redirecting prescribing toward anticonvulsants and antidepressants.
• Product and Segment View
  • Anticonvulsants are expected to lead with 57.3% of drug class demand in 2026, supported by clinical practice guideline recommendations.
  • Oral administration is expected to represent 68.5% of the route of administration segment, reflecting outpatient prescribing convenience.
  • Hospitals are expected to account for 52.6% of end-user demand, driven by specialist neurology and pain management clinic volumes.
• Geography and Competitive Outlook
  • South Korea (4.8%) is expected to lead growth, supported by pain management research investment and neurostimulation adoption.
  • The USA (4.7%) and Japan (4.6%) maintain strong growth driven by neurological condition prevalence and advanced treatment infrastructure.
  • Companies with combined pharmaceutical and device portfolios are expected to capture multimodal treatment protocol adoption.
• Analyst Opinion
  • The central pain syndrome management market is evolving from a pharmacologically dominated treatment category into a multimodal therapeutic space incorporating drug, device, and behavioral interventions.
  • Adoption of neuromodulation technologies is increasing as clinical evidence supports their use in treatment-resistant central pain.
  • The market is benefiting from the broader shift away from opioid-based pain management toward targeted neuropathic pain treatments.
  • Companies that can offer integrated pharmaceutical and device solutions aligned with evolving multimodal treatment protocols are expected to gain prescriber preference over the forecast period.

Key Takeaways

• The central pain syndrome management market was valued at USD 66.10 billion in 2025.
• By 2036, the Central Pain Syndrome Management Market is expected to be worth USD 146.45 billion.
• From 2026 to 2036, the market is projected to expand at a CAGR of 7.5%.
• The market is projected to create an incremental opportunity of USD 75.39 billion between 2026 and 2036.
• In 2026, anticonvulsants is expected to account for 57.3% of the drug class segment, driven by established efficacy in neuropathic pain modulation and widespread prescribing patterns across neurology and pain management clinics.
• South Korea (4.8%) and USA (4.7%) are two of the fastest growing markets in the world.

Central Pain Syndrome Management Market Definition

The central pain syndrome management market includes drug and device-based treatments for neuropathic pain caused by damage to the central nervous system. These treatments include anticonvulsants, antidepressants, neuromodulation devices, and supportive therapies that are available through hospitals, retail stores, and online pharmacies.

Central Pain Syndrome Management Market Inclusions

Market scope covers all commercially available central pain syndrome treatments categorized by drug class (anticonvulsants, antidepressants), route of administration (oral, intravenous), distribution channel (hospital pharmacy, retail pharmacy, online pharmacy, others), and end user (hospitals, clinics, others). Revenue coverage spans 2026 to 2036.

Central Pain Syndrome Management Market Exclusions

The scope does not include over-the-counter analgesics not prescribed for central pain syndrome, physical therapy services billed separately from pharmaceutical treatment, or diagnostic neuroimaging services.

Central Pain Syndrome Management Market Research Methodology

• Primary Research: FMI analysts talked to neurologists, pain management experts, and hospital pharmacy directors in important markets.
• Desk Research: This involved putting together information from drug prescription databases, sales records for neuromodulation devices, and publications of clinical practice guidelines.
• Market sizing and forecasting: bottom-up sizing by drug class, administration route, and end-user segments, along with regional pain management adoption curves.
• Data Validation: Checked every three months against prescription data, insurance claims databases, and records of medical device registrations.

Why is the Central Pain Syndrome Management Market Growing?

• Rising prevalence of neurological conditions including stroke, multiple sclerosis, and spinal cord injuries is expanding the patient population presenting with central pain syndrome, driving sustained pharmaceutical and device treatment demand.
• Advancement of neuromodulation technologies, including spinal cord stimulation and transcranial magnetic stimulation, is broadening the treatment options available beyond pharmacological management alone.
• Increasing clinical recognition of central pain syndrome as a distinct neurological condition is improving diagnostic accuracy and shifting treatment approaches from generic analgesic protocols toward targeted neuropathic pain management.

Demand for central pain syndrome management reflects the growing recognition of neuropathic pain as a distinct clinical entity requiring targeted therapeutic approaches rather than generic analgesic treatment. Anticonvulsants such as pregabalin and gabapentin have become standard first-line treatments, supported by clinical evidence demonstrating efficacy in modulating aberrant neural signaling associated with central nervous system damage.

Adoption of multimodal treatment approaches is increasing as clinical practice shifts toward combining pharmaceutical interventions with neuromodulation devices and behavioral therapy. Spinal cord stimulation and transcranial magnetic stimulation provide non-pharmacological pain relief options for patients who have inadequate response to drug therapy alone, expanding the treatment algorithm and total addressable market.

Pricing reflects the combination of generic pharmaceutical products and premium-priced neuromodulation devices. Anticonvulsants and antidepressants used in CPS management are predominantly available as generics, creating a cost-accessible base treatment tier. Device-based therapies including spinal cord stimulators and deep brain stimulation systems carry significantly higher per-patient costs but address the treatment-resistant segment of the patient population.

Market Segmentation Analysis

• Anticonvulsants make up 57.3% of the drug class segment, which shows that there is a consistent demand for them in the main application areas.
• Oral accounts for 68.5% of the route of administration segment, thanks to institutional procurement systems.
• Hospital Pharmacy is the biggest part of the distribution channel, with a 41.2% share. This is because clinical settings buy a lot of drugs at once.

The market for managing central pain syndrome is divided into drug class, route of administration, distribution channel, and end user.

Insights into the Anticonvulsants Drug Class Segment

Anticonvulsants maintain their position as the primary drug class for central pain syndrome management due to their demonstrated efficacy in neuropathic pain modulation. Pregabalin and gabapentin represent the most commonly prescribed agents, supported by clinical practice guidelines across multiple neurology and pain management professional organizations.

Insights into the Oral Route of Administration Segment

Oral administration leads the route of administration segment at 68.5%, reflecting the convenience and compliance advantages of oral anticonvulsant and antidepressant formulations. Outpatient prescribing patterns favor oral medications that enable long-term self-management.

Central Pain Syndrome Management Market Drivers, Restraints, and Opportunities

• Regulatory and structural demand drivers are creating sustained procurement patterns across established and emerging markets.
• Cost and access constraints create segmentation in adoption rates across healthcare systems with varying budget frameworks.
• Technology and product development are expanding treatment options and creating new market segments.

The central pain syndrome management market is shaped by regulatory requirements, technology evolution, and shifting procurement structures.

Neurological Condition Prevalence Growth

Demand is shaped by the increasing incidence of stroke, multiple sclerosis, and spinal cord injuries that result in central nervous system damage. Post-stroke central pain affects an estimated 8% to 10% of stroke survivors, creating a growing patient population proportional to overall stroke incidence.

Neuromodulation Technology Advancement

Growth reflects the development and clinical adoption of spinal cord stimulation, deep brain stimulation, and transcranial magnetic stimulation devices that provide non-pharmacological treatment options for patients with inadequate drug therapy response.

High Treatment Costs for Device-Based Therapies

Pricing for neuromodulation devices creates access barriers, particularly in healthcare systems with limited reimbursement coverage for implantable pain management technologies. Device costs constrain adoption to patients with documented treatment resistance.

Non-Opioid Treatment Preference Growth

Regulatory and clinical pressure to reduce opioid prescribing is redirecting pain management toward anticonvulsant, antidepressant, and neuromodulation-based approaches that address neuropathic pain without opioid dependence risk.

Analysis of Central Pain Syndrome Management Market By Key Countries

Country	CAGR
South Korea	4.8%
USA	4.7%
Japan	4.6%
EU	4.5%
UK	4.3%

• South Korea leads with 4.8% CAGR, supported by established infrastructure and investment programs.
• USA at 4.7% reflects expanding capabilities and modernization investment.
• Japan (4.6%) and EU (4.5%) maintain growth through institutional frameworks.

The global central pain syndrome management market is expected to grow at a rate of 7.5% per year from 2026 to 2036. The study covers more than 30 countries.

Demand Outlook for Central Pain Syndrome Management Market in South Korea

South Korea is expected to grow at 4.8% through 2036, supported by investment in pain management research, neurostimulation technology adoption, and expanding specialized pain clinic infrastructure.

• Pain management research investment supports treatment protocol development.
• Neurostimulation technology adoption expands non-pharmacological treatment options.
• Specialized pain clinic expansion improves diagnostic and treatment access.

Future Outlook for Central Pain Syndrome Management Market in the United States

The USA is expected to grow at 4.7% through 2036, driven by high neurological condition prevalence, FDA-approved neuromodulation devices, and non-opioid pain management treatment preference growth.

• High stroke and spinal cord injury prevalence sustains CPS patient population growth.
• FDA-approved neuromodulation devices expand treatment algorithm options.
• Non-opioid prescribing trends favor anticonvulsant and antidepressant use.

Opportunity Analysis of Central Pain Syndrome Management Market in Japan

Japan is expected to grow at 4.6% through 2036, supported by its aging population, advanced neurology infrastructure, and investment in precision pain management approaches.

• Aging population increases stroke-related central pain syndrome prevalence.
• Advanced neurology infrastructure supports comprehensive treatment delivery.
• Precision medicine investment drives personalized pain management approaches.

In-depth Analysis of Central Pain Syndrome Management Market in the European Union

The EU is expected to grow at 4.5% through 2036. Standardized pain management protocols, neurostimulation research programs, and multi-disciplinary treatment approaches support market development.

• EU pain management guidelines promote multimodal treatment approaches.
• Neurostimulation research programs advance non-pharmacological treatment options.
• Multi-disciplinary care frameworks improve treatment outcomes.

Sales Analysis of Central Pain Syndrome Management Market in the United Kingdom

The UK is expected to grow at 4.3% through 2036, driven by NHS pain management programs, expanding use of neuromodulation technologies, and growing emphasis on non-opioid chronic pain treatments.

• NHS chronic pain management programs support structured treatment access.
• Neuromodulation adoption in specialized pain centres expands treatment options.
• Non-opioid treatment emphasis redirects prescribing toward anticonvulsants.

Competitive Landscape and Strategic Positioning

• Pfizer Inc. leads with an estimated 20.0% market share.
• The competitive landscape includes global manufacturers with broad portfolios and specialized players.
• Entry barriers include regulatory requirements, established relationships, and scale-dependent advantages.

Pfizer Inc. leads the market through its established position with pregabalin (Lyrica), the most widely prescribed anticonvulsant for neuropathic pain management including central pain syndrome. The company benefits from brand recognition and extensive clinical evidence supporting prescribing patterns.

Eli Lilly and Company maintains a strong position through duloxetine (Cymbalta), a serotonin-norepinephrine reuptake inhibitor widely prescribed for chronic pain conditions including central pain syndrome.

Abbott Laboratories and Boston Scientific Corporation compete in the neuromodulation segment, providing spinal cord stimulation and deep brain stimulation devices for patients with treatment-resistant central pain.

Entry barriers include the established prescribing patterns for generic anticonvulsants, the high regulatory requirements for neuromodulation device approval, and the specialized clinical expertise required for device implantation procedures.

Key Companies in the Central Pain Syndrome Management Market

Key global companies leading the central pain syndrome management market include:

• Pfizer Inc. (USA), Eli Lilly and Company (USA), and GlaxoSmithKline plc (UK) hold leading pharmaceutical positions through established neuropathic pain drug portfolios.
• Abbott Laboratories (USA), Boston Scientific Corporation (USA), and Medtronic plc (Ireland) compete in the neuromodulation device segment with spinal cord stimulators and deep brain stimulation systems.
• Nevro Corp. (USA), NeuroMetrix, Inc. (USA), and Teva Pharmaceuticals (Israel) represent emerging positions through high-frequency stimulation technology and generic pain management formulations.

Competitive Benchmarking: Central Pain Syndrome Management Market

Company	Drug/Device Portfolio	Clinical Evidence	Market Access	Geographic Reach
Pfizer Inc.	High	Strong	Strong	Global
Eli Lilly and Company	Medium	Strong	Strong	Global
Abbott Laboratories	High	Strong	Moderate	Global
Boston Scientific Corporation	Medium	Strong	Moderate	Global
Medtronic plc	High	Strong	Moderate	Global
GlaxoSmithKline plc	Medium	Moderate	Strong	Global
Nevro Corp.	Low	Moderate	Low	N. America
Teva Pharmaceuticals	Medium	Moderate	Strong	Global
NeuroMetrix, Inc.	Low	Low	Low	N. America
Sanofi S.A.	Medium	Moderate	Strong	Global

Source: Future Market Insights competitive analysis, 2026.

Key Developments in Central Pain Syndrome Management Market

• In 2025, Pfizer Inc. continued research in central nervous system pain pathways through its broader neuropathic pain and non-opioid analgesic pipeline, focusing on improving safety and efficacy of chronic pain management therapies.
• In 2025, Abbott Laboratories expanded its neuromodulation portfolio by advancing spinal cord stimulation technologies, including closed-loop and adaptive stimulation systems for chronic and central neuropathic pain management applications.

Key Players in the Central Pain Syndrome Management Market

Major Global Players

• Pfizer Inc.
• Eli Lilly and Company
• Abbott Laboratories
• Boston Scientific Corporation
• Medtronic plc
• GlaxoSmithKline plc
• Nevro Corp.

Emerging Players/Startups

• Nevro Corp.
• NeuroMetrix, Inc.
• Teva Pharmaceuticals
• Sanofi S.A.
• Nalu Medical, Inc.

Report Scope and Coverage

Parameter	Details
Quantitative Units	USD 71.06 billion to USD 146.45 billion, at a CAGR of 7.5%
Market Definition	The central pain syndrome management market encompasses pharmaceutical and device-based treatments for neuropathic pain originating from central nervous system damage, including anticonvulsants, antidepressants, neuromodulation devices, and supportive therapies distributed through hospital, retail, and online pharmacy channels.
Regions Covered	North America, Latin America, Europe, East Asia, South Asia and Pacific, Middle East and Africa
Countries Covered	USA, UK, France, Germany, Italy, South Korea, Japan, China, India, 30 plus countries
Key Companies Profiled	Pfizer Inc., Eli Lilly and Company, Abbott Laboratories, Boston Scientific Corporation, Medtronic plc, GlaxoSmithKline plc, Nevro Corp., Teva Pharmaceuticals, NeuroMetrix, Inc., Sanofi S.A.
Forecast Period	2026 to 2036
Approach	Hybrid bottom-up and top-down methodology starting with verified transaction data, projecting adoption velocity across segments and regions.

Market Segmentation Analysis

Central Pain Syndrome Management Market Market Segmented by Drug Class:

• Anticonvulsants
• Antidepressants

Central Pain Syndrome Management Market Market Segmented by Route of Administration:

• Oral
• Intravenous

Central Pain Syndrome Management Market Market Segmented by Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Central Pain Syndrome Management Market Market Segmented by End User:

• Hospitals
• Clinics
• Others

Central Pain Syndrome Management Market Market by Region:

• North America
  • USA
  • Canada
  • Mexico
• Latin America
  • Brazil
  • Chile
  • Rest of Latin America
• Western Europe
  • Germany
  • UK
  • Italy
  • Spain
  • France
  • Nordic
  • BENELUX
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • Hungary
  • Balkan & Baltic
  • Rest of Eastern Europe
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia & New Zealand
  • Rest of South Asia and Pacific
• Middle East & Africa
  • Kingdom of Saudi Arabia
  • Other GCC Countries
  • Turkiye
  • South Africa
  • Other African Union
  • Rest of Middle East & Africa

Research Sources and Bibliography

• 1. International Association for the Study of Pain. (2025). IASP Guidelines on Central Neuropathic Pain Management. IASP.
• 2. USA Food and Drug Administration. (2024). FDA Approved Devices: Spinal Cord Stimulation Systems. FDA.
• 3. National Institute for Health and Care Excellence. (2025). NICE Clinical Guidelines: Neuropathic Pain in Adults. NICE.
• 4. American Academy of Neurology. (2024). AAN Practice Parameters: Central Pain Syndrome Treatment. AAN.
• 5. World Health Organization. (2024). WHO Model List of Essential Medicines: Anticonvulsants and Pain Management. WHO.

This bibliography is provided for reader reference. The full Future Market Insights report contains the complete reference list with publication dates, URLs, and supporting data for all cited works.

This Report Answers

• Estimating the market size and revenue from 2026 to 2036.
• Segmentation by drug class, route of administration, distribution channel, and end user.
• Regional and country-level insights across more than 30 markets.
• Technology analysis covering pharmaceutical and neuromodulation device treatment modalities.
• Competitive landscape assessment.
• Investment opportunity identification across pharmaceutical and device segments.
• Treatment algorithm and prescribing pattern analysis.
• Data delivery in PDF and Excel formats.